Product Overview
The RNF213 antibody is available in multiple formats, each optimized for specific research applications:
| Product | Clone | Host | Applications | Dilution | Source |
|---|
| EMD Millipore (MABN2510) | 1C9 | Mouse | ELISA, WB, IP, IHC | 1:500–1:1000 (WB) | |
| Abcam (ab238677) | Rabbit | ICC/IF | 1/266–1/500 | 1/266–1/500 | |
| Proteintech (21028-1-AP) | Rabbit | WB, IP, IHC | 1:500–1:1000 (WB) | 1:20–1:200 (IHC) | |
Key Features:
-
Specificity: Targets the N-terminal domain of RNF213 (e.g., clone 1C9 in EMD Millipore’s antibody).
-
Reactivity: Validated in human samples, including HUVEC cells (Proteintech) and A549 cells (Abcam).
Research Applications
RNF213 antibodies have been instrumental in elucidating the protein’s roles in:
| Study | Antibody Used | Key Findings | Source |
|---|
| Antimicrobial Defense | Proteintech | Demonstrated RNF213’s role in ubiquitinating bacterial lipopolysaccharide (LPS) | |
| Moyamoya Disease | EMD Millipore | Showed RNF213’s disruption in cerebral endothelial cells increased immune cell transmigration | |
| Treg Cell Regulation | Abcam | Identified RNF213’s promotion of Treg differentiation via K63-linked ubiquitination | |
Mechanistic Insights:
-
Lipid Metabolism: RNF213 inhibits lipolysis and regulates fatty acid desaturation (UniProtKB/Swiss-Prot, ).
-
Immune Signaling: Mediates ubiquitination of viral proteins (e.g., KSHV’s RTA) and bacterial components (e.g., Salmonella LPS) .
Clinical Implications
RNF213 antibodies are pivotal in studying diseases linked to RNF213:
-
Moyamoya Disease: RNF213 mutations impair BBB integrity, increasing immune cell infiltration .
-
Autoimmune Disorders: RNF213 promotes Treg differentiation, offering therapeutic potential for multiple sclerosis .